BlackRock Inc. Invests $39.52 Million in Emergent Biosolutions Inc. $EBS

Key Points

• BlackRock acquired a new 4.72 million-share stake in Emergent BioSolutions during the second quarter, valued at approximately $39.5 million and representing 9.14% of the company. Institutional investors collectively own 78.4% of EBS.
• Emergent reported quarterly revenue of $234.3 million and adjusted earnings of $0.60 per share, substantially beating analyst expectations of $177.5 million in revenue and a $0.08-per-share loss.
• EBS shares opened at $6.17, while analysts maintain a consensus “Hold” rating and an average price target of $10.00. Ratings remain mixed, with three Buy, one Hold and two Sell recommendations.

BlackRock Inc. bought a new stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,716,599 shares of the biopharmaceutical company's stock, valued at approximately $39,525,000. BlackRock Inc. owned approximately 9.14% of Emergent Biosolutions at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. bought a new position in shares of Emergent Biosolutions during the first quarter valued at $3,454,000. Dimensional Fund Advisors LP lifted its position in shares of Emergent Biosolutions by 22.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company's stock worth $22,884,000 after purchasing an additional 504,553 shares in the last quarter. Deutsche Bank AG bought a new position in Emergent Biosolutions in the 2nd quarter valued at $1,592,000. Evolve Private Wealth LLC bought a new position in Emergent Biosolutions in the first quarter valued at about $546,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Emergent Biosolutions by 13.7% in the 1st quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company's stock valued at $5,445,000 after purchasing an additional 78,900 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Stock Up 1.1%

Shares of NYSE:EBS opened at $6.17 on Wednesday. The company has a market capitalization of $316.34 million, a PE ratio of -1.74 and a beta of 2.34. Emergent Biosolutions Inc. has a 52-week low of $4.36 and a 52-week high of $14.06. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. The company has a fifty day moving average of $6.81 and a 200-day moving average of $7.99.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, equities analysts predict that Emergent Biosolutions Inc. will post -4.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares of the company's stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a report on Tuesday, August 11th. HC Wainwright cut their target price on Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They set an "underweight" rating for the company. Benchmark reissued a "buy" rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, UBS Group reiterated a "buy" rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $10.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source